T.E.M.

TEM Therapeutics is a biotechnology company focused on the intersection of tissue engineering and immunology to develop next-generation cell therapies. The company leverages its proprietary platform to engineer T-cells with enhanced durability and resistance to exhaustion, addressing key limitations in current CAR-T and TCR-T treatments. By integrating principles of regenerative medicine, TEM Therapeutics aims to improve the persistence and efficacy of adoptive cell transfers in treating solid tumors. Their research also extends to utilizing stem cell-derived products for tissue repair and immune modulation. The company is currently advancing several pre-clinical programs aimed at high-unmet-need oncology indications.